CB5138 Analogs

Key Highlights – CB5138 Analogs

CB5138 Analogs have been shown to:

  • Decrease expression of fibrosis biomarkers in co-cultures of lung cells and fibroblasts.
  • Decrease Ashcroft fibrosis score and lymphocytes in lung fluid after 21 days in prophylactic mouse model.
  • Demonstrate positive effects on all study outcomes in a therapeutic mouse model, including significantly reduced lung fibrosis as evidenced by decreases in the Ashcroft Score, fibrosis-related changes in lung weight, collagen deposition in lung tissue and collagen secretion into lung fluid.
  • Demonstrate significant reductions in lung fluid levels of a variety of pro-inflammatory cytokines and inflammatory cells in a therapeutic mouse model.

Why CB5138 Analogs?

Current treatment options for IPF are limited and poorly tolerated due to significant gastrointestinal and skin toxicity. Our CB5138 Analogs have impressive preclinical results, with anti-fibrotic properties comparable to those seen with nintedanib (the active ingredient in OFEV®), one of the two currently approved drugs for IPF. We also believe CB5138 Analogs have the potential to provide a better safter profile than currently approved IPF drugs.

Posters & White Papers

Broad Effects – Specific Mechanism Under Investigation

We have demonstrated through multiple preclinical studies that this family of peptides has broad anti-fibrotic and anti-inflammatory effects. Currently, CohBar scientists are exploring a variety of potential molecular targets to better elucidate the specific mechanism of action for CB5138 Analogs.